Procalcitonin: A Tool to Assist with Risk Assessment and Likelihood of Bacterial Co-infection in COVID-19

2^nd World Congress on Rare Diseases

June 30, 2021 | Webinar

Diane M. Borkowski

Thermo Scientific, Middletown, VA 22645

Scientific Tracks Abstracts: J Mol Genet Med

Abstract :

COVID-19 has dramatically impacted the modern healthcare system across the continuum of care. This session will explore the role of procalcitonin (PCT) in SARS-CoV-2 to aid in the differential diagnosis of bacterial coinfection, severity of bacterial burden and disease evolutionto determine the need for antimicrobial therapy. Antibiotic stewardship during the COVID-19 pandemic is a critical part of the comprehensive strategy to improve patient outcomes and reduce long-term adverse effects secondary to rising antibiotic resistance.

Biography :

Senior Medical Science Liaison for Thermo Fisher Scientific with a Bachelor of Science in Health Care Management and Nursing Diploma graduate with thirty+ years of professional experience in critical care. My clinical focus is to provide evidence-based information on biomarkers of infection, including Procalcitonin (PCT) along with resources which include: updated peer-reviewed publication lists; Grand Round / CME support, Clinical Professional Organizations, Critical Care, Antibiotic Stewardship & Sepsis Committee presentations, develop clinical education tools and protocol / order set consultation.
My clinical experience includes ICU/CCU, Interventional Cardiology / Radiology and ED in various positions: staff, management and education. I have published on thrombolytics, provided educational programs for CE credit and served on a nursing journal editorial board.